A similar finding was previously reported in rituximab and fingolimod treatment,10 yet others reported no significant changes during ocrelizumab treatment.11 While awaiting future data, a low JCV index in MS patients treated with ocrelizumab should not necessarily be interpreted as JCV sero-negativity or a low PML risk category. Here, PML is linked to myeloid sarcoma.